Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Founder’s Role in the Development of Venture’s Factors of Content Production – Biographical Notes by Aviva Lev-Ari, PhD, RN, LPBI Group

 

I would say, yes, 1 to 7 brought to the immaculate CONCEPTION on LPBI Group, launching a Journal to publish the combination drug therapy, I developed !!

My academic and technical training is very unique:

1. it was my MASTERS in planning at HUJI, GPA 95
2. The conceptualization modeling I did at Technion, independently
3. It was the PhD in Industrial Organization Economics at Berkeley, and the business portfolio analytics inside my dissertation chapters 6 to 9
4. My concept development at SRI, MITRE, PSC (software Pricing Models, valuation of search algorithms) and modeling at McGraw-Hill
5. My 15 courses in biological science at NEU.edu in 2005
6. My RN, three years, 70 units, plus PharmacoTherapy research with my Prof. of Pharmacology, developing on my own a combination drug therapy, bring the professor to be stunned, he was not familiar with one of the three drug, never thought of that drug combination  for cardiovascular before, six papers, followed.
7. My five years in Hearth care delivery at MGH, BIDMC, Waltham Hospital and post acute skilled nursing facilities as Clinical Nurse Manager.

It is my belief that, no MBA can do 1 to 18, below, and no PhD or MD or RN, but 1 to 7, above AND

It was meant to be that I had met on LinkedIn, Dr. Larry H. Bernstein, MD, FCAP that has joined LPBI Group in 7/2012. LPBI Group is a Team effort, “Larry and Aviva were one DYAD.” It was the engine in content creation by co-curation, 7/2012 – 6/21/2016!!!

The description of Founder’s roles includes the following:

1. Was the Developer of the curation methodology, and the training of the entire team, transitioning from Academic publication style to Open access online Journal style.

 

2. Was the Designer of the policies of engagement on Social Media (Tweeter, Facebook, LinkedIn), leading to 1.5 Million eReaders, 400,000 read what Aviva posted !! 7,300 scientific comments by International scientists on 5,500 articles, 10,000 tags for these articles

 

3. Was the Developer of the original Journal Ontology, I started with 27 research categories, the team augmented the ontology to 700, Larry thrived in this development effort

 

4. E-Books: Had created the architecture of Five Medical Specialties for our BioMed e-Series and formulated the Titles on the 16 volumes: cardiovascular, genomics, cancer, immunology, precision medicine

 

5. Had created the methodology of creation of electronic Table of Contents of books from the Journal archive by research categories as feeders

 

6. Had create the style across all articles, across all books, across all e-Proceedings

 

7. Had designed the cover page of 16 books, with Dr. Williams selection of color theme per series and creation of three collages from art work I provided

 

8. Had commissioned article titles to each Team member, 4/2012 to Present

 

9. Had clicked on the “Publish” button 3,400 times, curation, reporting, pages of the WEBSITE’s Site Map

 

10. Was, in person, in attendance at +60 conferences that ALL started at 8AM for three days on average each for the real time press coverage, sending the link to the e-Proceedings to Chief Editors of Science, Cell, Nature

 

11. Had developed the methodology of REAL TIME press coverage with social media on pharmaceuticalintelligence.com

 

12. Had developed the Executive Summary, the content used in the PowerPoint presentation and this week the Opportunities Maps with inputs from Amnon and Rick offered in 12/2018.

 

13. Had developed the ALGORITHM for valuation of the Journal, “curated article” given 20x bigger score than “reported article”, two types of articles to price by multiple parameters. One curated article , then ALL Curations, o, ne reported article then ALL reported articles, THEN across two groups for value of the Journal for sale. Development DONE, population with data assigned to Ritu Saxena, PhD.

• Financial Valuation of Three Health Care Intellectual Property (IP) Content Asset Classes

14. Am developing the ALGORITHMS for valuation of the books, one THEN 16, as soon as scores computed for every article in the Journal, scores will be carried over to all article in each VOLUME, # words per article is available, # eReader per article is given by hosting company, other parameters are created.

• Global Market Penetration Forecast for each Volume in the 16 Volume BioMed e-Series

15. Am developing the ALGORITHMS for valuation of the e-Proceedings, one THEN 60
16. Am bringing to the Table Investment Bankers  (IB) in Israel in the US

Type one: strictly Health care IBs

Type two: Media and Content IBs

17. Am bringing to the Table Legal Advisory service providers in Israel in the US

 

18. Had added two gifted Business Development  (BD) professionals, interviewed by me and MF:

– AD in Israel

– RM in UT

and

– GT, ex-Merck, marketing communications with us since brilliantly contributed as Co-Editor of Voices of Patients, vol 1 Series E.

Our BDs execute, use my contents, recreate artifacts and hopefully will initiate with high productivity, as described for 1 to 18, above.

These Activities had yielded the following Artifacts:

• Executive Summary
• Opportunities Map in the Acquisition Arena
• Dynamic Contents for LPBI Group’s PowerPoint Presentation
• Detailed Technology Description
• Curation Methodology – Digital Communication Technology to mitigate Published Information Explosion and Obsolescence in Medicine and Life Sciences
• Top Authors by Number of eReaders Views
• Top Articles by Number of e-Readers for All Days ending 2019-02-17
• LPBI Group’s Social Media Presence
• Financial Valuation of Three Health Care Intellectual Property (IP) Content Asset Classes
• Global Market Penetration Forecast for each Volume in the 16 Volume BioMed e-Series
• Potential Use of LPBI IP as Value Price Driver by Potential Acquirer: Assumptions per Asset Class 
• Financial Advisory & Legal Advisory Providers: US & Israel

Additional Biographical Accounts:

 

1. Reflections on a Four-phase Career

Dr. Lev-Ari’s career, as presented in Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018, has the following phases:

• Phase 1: Research, 1973 – 1983
• Phase 2: Corporate Applied Research in the US, 1985 – 2005
• Phase 3: Career Reinvention in Health Care, 2005 – 2012
• Phase 4: Electronic Scientific Publishing, 4/2012 to present

https://pharmaceuticalintelligence.com/2018/03/06/reflections-on-a-four-phase-career-aviva-lev-ari-phd-rn-march-2018/

 

2. Recollections of Years at UC, Berkeley, Part 1 and Part 2

• Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other professors and other peers

https://pharmaceuticalintelligence.com/2018/03/15/recollections-my-days-at-berkeley-9-1978-12-1983-about-my-doctoral-advisor-allan-pred-other-professors-and-other-peer/

• Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83

https://pharmaceuticalintelligence.com/2018/05/24/recollections-part-2-while-rolling-is-preceded-by-while-enrolling-autobiographical-alumna-recollections-of-berkeley-aviva-lev-ari-phd83/

 

3. Achievements in Three Academic Disciplines

3.1       Pioneering implementations of Analytics to Business decision making

Pioneering implementations of analytics to business decision making: contributions to domain knowledge conceptualization, research design, methodology development, data modeling and statistical data analysis: Aviva Lev-Ari, UCB, PhD’83; HUJI MA’76

https://pharmaceuticalintelligence.com/2018/05/28/pioneering-implementations-of-analytics-to-business-decision-making-contributions-to-domain-knowledge-conceptualization-research-design-methodology-development-data-modeling-and-statistical-data-a/

 

3.2       Key Opinion Leader (KOL) in Pharmaceutical Business Intelligence

Digital KOL Parameters

Key Opinion Leader (KOL) – Aviva Lev-Ari, PhD, RN, as evidenced by

https://pharmaceuticalintelligence.com/2016/07/21/key-opinion-leader-kol-aviva-lev-ari-phd-rn-as-evidenced-by/

 

4. Thriving at the Survival Calls during Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL

Author and Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/06/11/thriving-at-the-survival-calls-during-careers-in-the-digital-age-an-age-like-no-other-also-known-as-digital/

 

5.  Data Science is the Greatest Science! It is the Greatest Science for Women, as well

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/03/12/data-science-is-the-greatest-science-it-is-the-greatest-science-for-women-as-well/